Please ensure Javascript is enabled for purposes of website accessibility

Why Lucira Health Stock Skyrocketed Today

By Prosper Junior Bakiny - Apr 12, 2021 at 5:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's COVID-19 Test Kit will soon be available for sale at a pharmacy near you.

What happened?

Shares of medical technology company Lucira Health (LHDX 0.00%) rose sharply on Monday and ended the day up by 27% after climbing by as much as 41.3% earlier in the trading session. The reason for these gains was the fact that the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the company's Lucira Check It COVID-19 Test Kit for over-the-counter (OTC) sale. 

So what

The Lucira Check It Test Kit, the first self-administered COVID-19 test approved by the FDA, can be used from the comfort of one's own home and delivers "PCR quality molecular accuracy in 30 minutes or less."

While results from lab tests can take anywhere from several days to two weeks, Lucira Health's test kit delivers quality results in less than an hour. Plenty of other diagnostic tests for COVID-19 have been granted EUA by the FDA. And in fact, it seems at first glance that the healthcare company may not benefit a whole lot from this milestone.

Piggy bank wearing a face mask.

Image source: Getty Images.

After all, with coronavirus vaccines becoming more and more widespread, there will likely be less of a need for test kits for the disease. But the OTC availability of this test will drastically improve its accessibility, which could lead to a significant increase in sales for Lucira Health. That explains why investors are bidding up the company's shares today despite unimpressive, preliminary, first-quarter top-line projections. Lucira Health expects to record between $4 million and $4.5 million in net revenue during Q1 2021, which comes short of the $11.71 million analysts are expecting on average.

Now what

According to the research firm Grand View Research, the COVID-19 testing market will expand at a compound annual growth rate (CAGR) of 5.05% between 2021 and 2027. Thanks to the FDA's decision to approve its test kit for OTC sale, Lucira Health looks well positioned to profit from this market in the coming months and years. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lucira Health, Inc. Stock Quote
Lucira Health, Inc.
LHDX
$1.86 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.